Hemoperfusion removal of digoxin from dogs. 1978

T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich

Removal of digoxin by XAD-4 hemoperfusion columns was tested after four dogs were given 0.06 mg/kg of digoxin i.v. Dogs were perfused for 4 to 5 hr at a flow of 105 ml/min through a 100 gm XAD-4 column 16 hr after the dose. Pharmacokinetic analysis of digoxin levels was performed with a three-compartment model. The apparent postdistribution t1/2 was 16.0 +/- 2.9 (S.D.) hr and decreased to 7.1 +/- 2.1 hr during perfusion. Digoxin perfusion clearance was 46 ml/min. An average of 51 microgram of digoxin was recovered from used columns. CP of digoxin calculated from the total R was 127.5 +/- 13 ml/min or 2.3 times greater than plasma flow. With the use of 3H-digoxin, canine blood was found to contain 2.5 times as much digoxin as did plasma. After perfusion there was an increase in serum digoxin levels in all dogs. Computer analysis showed that the increase in plasma digoxin levels immediately after hemoperfusion occurred because the central compartment, which was depleted of digoxin during hemoperfusion, was refilled from peripheral compartments. This study demonstrated that (1) XAD-4 hemoperfusion doubles the rate of removal of digoxin from dogs, (2) dog whole blood contains more than twice as much digoxin than does plasma, so that hemoperfusion clearance exceeds plasma flow, and (3) a multicompartmental pharmacokinetic model explains the increase in serum digoxin concentrations observed at the completion of hemoperfusion.

UI MeSH Term Description Entries
D008297 Male Males
D008658 Inactivation, Metabolic Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion. Detoxication, Drug, Metabolic,Drug Detoxication, Metabolic,Metabolic Detoxication, Drug,Detoxification, Drug, Metabolic,Metabolic Detoxification, Drug,Metabolic Drug Inactivation,Detoxication, Drug Metabolic,Detoxication, Metabolic Drug,Detoxification, Drug Metabolic,Drug Inactivation, Metabolic,Drug Metabolic Detoxication,Drug Metabolic Detoxification,Inactivation, Metabolic Drug,Metabolic Drug Detoxication,Metabolic Inactivation
D010949 Plasma The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION. Blood Plasma,Fresh Frozen Plasma,Blood Plasmas,Fresh Frozen Plasmas,Frozen Plasma, Fresh,Frozen Plasmas, Fresh,Plasma, Blood,Plasma, Fresh Frozen,Plasmas,Plasmas, Blood,Plasmas, Fresh Frozen
D011137 Polystyrenes Polymerized forms of styrene used as a biocompatible material, especially in dentistry. They are thermoplastic and are used as insulators, for injection molding and casting, as sheets, plates, rods, rigid forms and beads. Polystyrol,Polystyrene,Polystyrols
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D012117 Resins, Synthetic Polymers of high molecular weight which at some stage are capable of being molded and then harden to form useful components. Dental Resins,Dental Resin,Resin, Dental,Resin, Synthetic,Resins, Dental,Synthetic Resin,Synthetic Resins
D001825 Body Fluid Compartments The two types of spaces between which water and other body fluids are distributed: extracellular and intracellular. Body Fluid Compartment,Compartment, Body Fluid,Compartments, Body Fluid,Fluid Compartment, Body,Fluid Compartments, Body
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006464 Hemoperfusion Removal of toxins or metabolites from the circulation by the passing of blood, within a suitable extracorporeal circuit, over semipermeable microcapsules containing adsorbents (e.g., activated charcoal) or enzymes, other enzyme preparations (e.g., gel-entrapped microsomes, membrane-free enzymes bound to artificial carriers), or other adsorbents (e.g., various resins, albumin-conjugated agarose). Hemosorption,Hemoperfusions,Hemosorptions

Related Publications

T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
November 1978, Artificial organs,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
July 1981, The International journal of artificial organs,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
October 1977, The American journal of gastroenterology,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
November 1980, Clinical toxicology,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
January 1988, Drug intelligence & clinical pharmacy,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
July 1980, JAMA,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
May 1979, Artificial organs,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
September 1980, Kidney international. Supplement,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
October 1980, JAMA,
T P Gibson, and S V Lucas, and H A Nelson, and A J Atkinson, and G T Okita, and P Ivanovich
December 1978, JAMA,
Copied contents to your clipboard!